Lexaria Bioscience (LEXX) EBT Margin Growth (3y) (2020 - 2026)
Lexaria Bioscience (LEXX) EBT Margin Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -484.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 132.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 6,685.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -2,054.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8,006.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 9,980.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -9,922.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 31,363.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -5,319.00 |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -49,161.00 |
| Aug 31, 2025 | -87,021.00 |
| May 31, 2025 | 29,912.00 |
| Feb 28, 2025 | 340,872.00 |
| Nov 30, 2024 | 1.36 Mn |
| Aug 31, 2024 | 171,395.00 |
| May 31, 2024 | -195,304.00 |
| Feb 29, 2024 | -13,844.00 |
| Nov 30, 2023 | -78,174.00 |
| Aug 31, 2023 | -206,782.00 |
| May 31, 2023 | 97,720.00 |
| Feb 28, 2023 | -367,992.00 |
| Nov 30, 2022 | 1.67 Mn |
| Aug 31, 2022 | 85,129.00 |
| May 31, 2022 | 149,862.00 |
| Feb 28, 2022 | 302,714.00 |
| Nov 30, 2021 | -73,265.00 |
| Aug 31, 2021 | 363,670.00 |
| May 31, 2021 | 442,789.00 |
| Feb 28, 2021 | 242,625.00 |